Table 4. Protection of guinea pigs (n = 5) against FMDV challenge.
| Group a | Vaccines | Protection | Primary vesicles | Second vesicles |
|---|---|---|---|---|
| A | NC8 (pSIP411-VP1) | 4/5 | 5/5 | 1/5 |
| B | NC8 (pSIP411) | 2/5 | 5/5 | 3/5 |
| C | WCFS1 (pSIP411-VP1) | 5/5 | 5/5 | 0/5 |
| D | WCFS1 (pSIP411) | 3/5 | 5/5 | 2/5 |
| E | Only milk | 1/5 | 5/5 | 4/5 |
Severe symptoms were based on daily monitoring until 7 days post challenge (one guinea pig of each group was chosen to determine the proliferation of spleen lymphocytes and the number of remaining animals in each group was 5).
a Guinea pigs were challenged on day 40. Animals showing FMD-compatible lesions only at the original injection site as primary vesicles were judged to be protected, and those showing any FMD clinical signs in the other three feet as second vesicles were judged to be unprotected.